Etranacogene dezaparvovec-drlb gene therapy for patients with hemophilia B (congenital factor IX deficiency)

References

• World Federation of Hemophilia. Report on the annual global survey 2021 [ updated Oct 2022; cited 2023 Apr 29]. Available from: https://www1.wfh.org/publications/files/pdf-2324.pdf
   Google Scholar
• Soucie JM, Miller CH, Dupervil B, et al. Occurrence rates of haemophilia among males in the United States based on surveillance conducted in specialized haemophilia treatment centres. Haemophilia. 2020;26(3):487–493. doi: 10.1111/hae.13998
   PubMed Web of Science ®Google Scholar
• Blanchette VS, Key NS, Ljung LR, et al. Definitions in hemophilia: communication from the SSC of the ISTH. J Thromb Haemost. 2014;12(11):1935–1939. doi: 10.1111/jth.12672
   PubMed Web of Science ®Google Scholar
• Darby SC, Kan SW, Spooner RJ, et al. Mortality rates, life expectancy, and causes of death in people with hemophilia a or B in the United Kingdom who were not infected with HIV. Blood. 2007;110(3):815–825. doi: 10.1182/blood-2006-10-050435
   PubMed Web of Science ®Google Scholar
• Måseide RJ, Berntorp E, Astermark J, et al. Joint health and treatment modalities in Nordic patients with moderate haemophilia a and B - The MoHem study. Haemophilia. 2020;26(5):891–897. doi: 10.1111/hae.14114
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. Press Release. FDA approves first gene therapy to treat adults with hemophilia B [ updated 2022 Nov 22; cited 2023 Jun 22]. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapy-treat-adults-hemophilia-b
   Google Scholar
• Manco-Johnson MJ, Abshire TC, Shapiro AD, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med. 2007;357(6):535–544. doi: 10.1056/NEJMoa067659
   PubMed Web of Science ®Google Scholar
• Collins PW, Obaji SG, Roberts H, et al. Clinical phenotype of severe and moderate haemophilia: who should receive prophylaxis and what is the target trough level? Haemophilia. 2021;27(2):192–198. doi: 10.1111/hae.14201
   PubMed Web of Science ®Google Scholar
• Srivastava A, Santagostino E, Dougall A, et al. WFH guidelines for the management of hemophilia panelists and co-authors. WFH guidelines for the management of hemophilia, 3rd edition. Haemophilia. 2020;26(Suppl 6):1–158. Erratum in: Haemophilia. 27(4):699. 2021. doi: 10.1111/hae.14046
   PubMed Web of Science ®Google Scholar
• Oldenburg J. Optimal treatment strategies for hemophilia: achievements and limitations of current prophylactic regimens. Blood. 2015;125(13):2038–2044. doi:10.1182/blood-2015-01-528414
   PubMed Web of Science ®Google Scholar
• Powell JS, Pasi KJ, Ragni MV, et al. Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B. N Engl J Med. 2013;369(24):2313–2323. doi: 10.1056/NEJMoa1305074
   PubMed Web of Science ®Google Scholar
• Santagostino E, Martinowitz U, Lissitchkov T, et al. Long-acting recombinant coagulation factor IX albumin fusion protein (rIX-FP) in hemophilia B: results of a phase 3 trial. Blood. 2016;127(14):1761–1769. doi: 10.1182/blood-2015-09-669234
   PubMed Web of Science ®Google Scholar
• Rebinyn® Prescribing Information. Novo Nordisk Inc. Plainsboro, NJ [ updated Aug 2022; cited 2023 Oct 22]. Available from: https://www.novo-pi.com/rebinyn.pdf
   Google Scholar
• Nichols TC, Levy H, Merricks E, et al. Preclinical evaluation of a next-generation, subcutaneously administered, coagulation factor IX variant, dalcinonacog alfa. PLoS One. 2020;15(10):e0240896. doi: 10.1371/journal.pone.0240896
   PubMed Web of Science ®Google Scholar
• Mahlangu J, Levy H, Lee M, et al. Efficacy and safety of subcutaneous prophylaxis with dalcinonacog alfa in adults with haemophilia B. Haemophilia. 2021;27(4):574–580. doi: 10.1111/hae.14315
   PubMed Web of Science ®Google Scholar
• Male C, Andersson NG, Rafowicz A, et al. Inhibitor incidence in an unselected cohort of previously untreated patients with severe haemophilia B: a PedNet study. Haematologica. 2020;106(1):123–129. doi: 10.3324/haematol.2019.239160
   Web of Science ®Google Scholar
• Eichler H, Angchaisuksiri P, Kavakli K, et al. A randomized trial of safety, pharmacokinetics and pharmacodynamics of concizumab in people with hemophilia a. J Thromb Haemost. 2018;16(11):2184–2195. doi: 10.1111/jth.14272
   PubMed Web of Science ®Google Scholar
• Mahlangu J, Luis Lamas J, Cristobal Morales J, et al. Long-term safety and efficacy of the anti-tissue factor pathway inhibitor marstacimab in participants with severe haemophilia: phase II study results. Br J Haematol. 2023;200(2):240–248. doi: 10.1111/bjh.18495
   PubMed Web of Science ®Google Scholar
• Sehgal A, Barros S, Ivanciu L, et al. An RNAi therapeutic targeting antithrombin to rebalance the coagulation system and promote hemostasis in hemophilia. Nat Med. 2015;21(5):492–497. doi: 10.1038/nm.3847
   PubMed Web of Science ®Google Scholar
• Shapiro AD, Angchaisuksiri P, Astermark J, et al. Long-term efficacy and safety of subcutaneous concizumab prophylaxis in hemophilia a and hemophilia A/B with inhibitors. Blood Adv. 2022;6(11):3422–3432. doi: 10.1182/bloodadvances.2021006403
   PubMed Web of Science ®Google Scholar
• Hemophilia Federation of America. Press Release. FDA issues response to novo Nordisk’s request for concizumab approval [ updated 2023 May 11; cited 2023 Jun 22]. Available from: https://www.hemophiliafed.org/fda-issues-crl-for-novo-nordisks-concizumab/#:~:text=Recently%20Novo%20Nordisk%20received%20a,with%20inhibitors%20in%20August%202022
   Google Scholar
• Keam SJ. Concizumab: first approval. Drugs. 2023. epub ahead of print. doi:10.1007/s40265-023-01912-6
   Google Scholar
• Young G, Srivastava A, Kavakli K, et al. Efficacy and safety of fitusiran prophylaxis in people with haemophilia a or haemophilia B with inhibitors (ATLAS-INH): a multicentre, open-label, randomised phase 3 trial. Lancet. 2023 Apr 29;401(10386):1427–1437. doi: 10.1016/S0140-6736(23)00284-2
   PubMed Web of Science ®Google Scholar
• Srivastava A, Rangarajan S, Kavakli K, et al. Fitusiran prophylaxis in people with severe haemophilia a or haemophilia B without inhibitors (ATLAS-A/B): a multicentre, open-label, randomised, phase 3 trial. Lancet Haematol. 2023;10(5):e322–32. doi: 10.1016/S2352-3026(23)00037-6
   PubMed Web of Science ®Google Scholar
• White GC 2nd, Rosendaal F, Aledort LM, et al. Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost. 2001;85(3):560. doi: 10.1055/s-0037-1615621
   PubMed Web of Science ®Google Scholar
• Manno CS, Chew AJ, Hutchison S, et al. AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. Blood. 2003;101(8):2963–2972. doi: 10.1182/blood-2002-10-3296
   PubMed Web of Science ®Google Scholar
• High KA, Manno CS, Sabatino DE, et al. Immune responses to AAV and to factor IX in a phase I study of AAV-mediated liver-directed gene transfer for hemophilia B. Blood. 2003;102(11):154a–155a.
   Web of Science ®Google Scholar
• Nathwani AC, Tuddenham EG, Rangarajan S, et al. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med. 2011;365(25):2357–2365. doi: 10.1056/NEJMoa1108046
   PubMed Web of Science ®Google Scholar
• Nathwani AC, Reiss UM, Tuddenham EGD, et al. Long-term safety and efficacy of factor IX gene therapy in hemophilia B. N Engl J Med. 2014;371(21):1994–2004. doi: 10.1056/NEJMoa1407309
   PubMed Web of Science ®Google Scholar
• Nathwani AC, Reiss U, Tuddenham E, et al. Adeno-associated mediated gene transfer for hemophilia B: 8 year follow up and impact of removing “empty viral particles” on safety and efficacy of gene transfer. Blood. 2018;132(Suppl 1):491. doi: 10.1182/blood-2018-99-118334
   Google Scholar
• Nathwani AC. Gene therapy for hemophilia. Hematology Am Soc Hematol Educ Program. 2022;2022(1):569–578. doi:10.1182/hematology.2022000388
   PubMedGoogle Scholar
• Simioni P, Tormene D, Tognin G, et al. X-linked thrombophilia with a mutant factor IX (factor IX Padua). N Engl J Med. 2009;361(17):1671–1675. doi: 10.1056/NEJMoa0904377
   PubMed Web of Science ®Google Scholar
• Spronck EA, Liu YP, Lubelski J, et al. Enhanced factor IX activity following administration of AAV5-R338L “Padua” factor IX versus AAV5 WT human factor IX in NHPs. Mol Ther Methods Clin Dev. 2019;15:221–231. doi: 10.1016/j.omtm.2019.09.005
   PubMed Web of Science ®Google Scholar
• Miesbach W, Meijer K, Coppens M, et al. Gene therapy with adeno-associated virus vector 5-human factor IX in adults with hemophilia B. Blood. 2018;131(9):1022–1031. doi: 10.1182/blood-2017-09-804419
   PubMed Web of Science ®Google Scholar
• EudraLex. European Commission for Public Health. Good manufacturing practice (GMP) guidelines. Volume 4 [ cited 2023 May 7]. Available from: https://health.ec.europa.eu/medicinal-products/eudralex/eudralex-volume-4_en
   Google Scholar
• Sen D, Balakrishnan B, Gabriel N, et al. Improved adeno-associated virus (AAV) serotype 1 and 5 vectors for gene therapy. Sci Rep. 2013;3(1):1832. doi: 10.1038/srep01832
   PubMedGoogle Scholar
• Boutin S, Monteilhet V, Veron P, et al. Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors. Hum Gene Ther. 2010;21(6):704–712. doi: 10.1089/hum.2009.182
   PubMed Web of Science ®Google Scholar
• Stanford S, Pink R, Creagh D, et al. Adenovirus-associated antibodies in UK cohort of hemophilia patients: a seroprevalence study of the presence of adenovirus-associated virus vector-serotypes AAV5 and AAV8 neutralizing activity and antibodies in patients with hemophilia a. Res Pract Thromb Haemost. 2019;3(2):261–267. doi: 10.1002/rth2.12177
   PubMed Web of Science ®Google Scholar
• Miesbach W, Meijer K, Coppens M, et al. Five year data confirms stable FIX expression and sustained reductions in bleeding and factor IX use following AMT-060 gene therapy in adults with severe or moderate-severe hemophilia B [abstract]. Res Pract Thromb Haemost. 2021;5. https://abstracts.isth.org/abstract/five-year-data-confirms-stable-fix-expression-and-sustained-reductions-in-bleeding-and-factor-ix-use-following-amt-060-gene-therapy-in-adults-with-severe-or-moderate-severe-hemophilia-b/
   Google Scholar
• Von Drygalski A, Giermasz A, Castaman G, et al. Etranacogene dezaparvovec (AMT-061 phase 2b): normal/near normal FIX activity and bleed cessation in hemophilia B. Blood Adv. 2019;3(21):3241–3247. Erratum in: Blood Adv. 4(15):3668. 2020. doi: 10.1182/bloodadvances.2019000811
   PubMed Web of Science ®Google Scholar
• Von Drygalski A, Gomez E, Giermasz A, et al. Stable and durable factor IX levels in hemophilia B patients over 3 years post etranacogene dezaparvovec gene therapy. Blood Adv. 2023 Dec 9;7(19):5671–5679. doi: 10.1182/bloodadvances.2022008886
   PubMed Web of Science ®Google Scholar
• Pipe SW, Leebeek FWG, Recht M, et al. Gene therapy with Etranacogene Dezaparvovec for hemophilia B. N Engl J Med. 2023;388(8):706–718. doi: 10.1056/NEJMoa2211644
   PubMed Web of Science ®Google Scholar
• Meliani A, Leborgne C, Triffault S, et al. Determination of anti-adeno-associated virus vector neutralizing antibody titer with an in vitro reporter system. Hum Gene Ther Methods. 2015;26(2):45–53. doi: 10.1089/hgtb.2015.037
   PubMed Web of Science ®Google Scholar
• Majowicz A, Nijmeijer B, Lampen MH, et al. Therapeutic hFIX Activity achieved after single AAV5-hFIX treatment in hemophilia B patients and NHPs with pre-existing anti-AAV5 NABs. Mol Ther Methods Clin Dev. 2019;14:27–36. doi: 10.1016/j.omtm.2019.05.009
   PubMed Web of Science ®Google Scholar
• Alprolix® Prescribing Information. Sanofi. Waltham: MA [ updated 2023 May; cited 2023 Oct 25]. Available from: https://products.sanofi.us/Alprolix/alprolix.html
   Google Scholar
• Mancuso ME, Lubetsky A, Pan-Petesch B, et al. Long-term safety and efficacy of rIX-FP prophylaxis with extended dosing intervals up to 21 days in adults/adolescents with hemophilia B. J Thromb Haemost. 2020;18(5):1065–1074. doi: 10.1111/jth.14778
   PubMed Web of Science ®Google Scholar
• Foley JH, Shehu E, Riddell A, et al. Differences in wild-type- and R338L-tenase complex formation are at the root of R338L-factor IX assay discrepancies. Blood Adv. 2023;7(3):458–467. doi: 10.1182/bloodadvances.2022007435
   PubMed Web of Science ®Google Scholar
• Robinson MM, George LA, Carr ME, et al. Factor IX assay discrepancias i nthe setting of liver gene therapy using a hyperfunctional variant factor IX-Padua. J Thromb Haemost. 2021;19(5):1212–1218. doi: 10.1111/jth.15281
   PubMed Web of Science ®Google Scholar
• Truedsson Å, Schmidt DE, Strålfors A, et al. One-stage versus chromogenic factor IX activity in haemophilia B [abstract]. Res Pract Thromb Haemost. 2020 Accessed May 31, 2023; 4(Suppl 1). Available from: https://abstracts.isth.org/abstract/one-stage-versus-chromogenic-factor-ix-activity-in-haemophilia-b/
   Google Scholar
• Schmidt M, Foster GR, Coppens M, et al. Molecular evolution and vector integration analysis of HCC complicating AAV gene therapy for hemophilia B. Blood Adv. 2023;7(17):4966–4969. doi: 10.1182/bloodadvances.2023009876
   PubMed Web of Science ®Google Scholar
• Cision PR Newswire. Press Release. Marburg, Germany. First gene therapy for hemophilia B, CSL’s Hemgenix®, approved by the European Commission [ updated 2023 Feb 20; cited 2023 Jun 22]. Available from: https://newsroom.csl.com/2023-02-20-First-Gene-Therapy-for-Hemophilia-B,-CSLs-HEMGENIX-R-,-Approved-by-the-European-Commission
   Google Scholar
• Pharmafile. Press Release. Haywards Heath, England. MHRA grants conditional marketing authorization in Great Britain to CSL’s Hemgenix® (etranacogene dezaparvovec) as first gene therapy for haemophilia B [ updated 2023 Mar 27; cited 2023 Jun 22]. Available from: https://pharmafile.com/news/mhra-grants-conditional-marketing-authorisation-great-britain-csl-s-hemgenix-etranacogene-de/
   Google Scholar
• Samelson-Jones BJ, Sullivan SK, Rasko JEJ, et al. Follow-up of more than 5 years in a cohort of patients with hemophilia B treated with fidanacogene elaparvovec adeno-associated virus gene therapy. Blood. 2021;138(Supplement 1):3975–3975. doi: 10.1182/blood-2021-150541
   Google Scholar
• Shah J, Kim H, Sivamurthy K, et al. Comprehensive analysis and prediction of long-term durability of factor IX activity following etranacogene dezaparvovec gene therapy in the treatment of hemophilia B. Curr Med Res Opin. 2023;39(2):227–237. doi: 10.1080/03007995.2022.2133492
   PubMed Web of Science ®Google Scholar
• Heinke P, Rost F, Rode J, et al. Diploid hepatocytes drive physiological liver renewal in adult humans. Cell Syst. 2022;13(6):499–507.e12. doi: 10.1016/j.cels.2022.05.001
   PubMed Web of Science ®Google Scholar
• Muhuri M, Levy DI, Schulz M, et al. Durability of transgene expression after rAAV gene therapy. Mol Ther. 2022;30(4):1364–1380. doi: 10.1016/j.ymthe.2022.03.004
   PubMed Web of Science ®Google Scholar
• Regling K, Callaghan MU, Sidonio R Jr. Managing severe hemophilia a in children: pharmacotherapeutic options. Pediatric Health Med Ther. 2022;13:27–35. doi:10.2147/PHMT.S293246
   PubMed Web of Science ®Google Scholar
• Dalwadi DA, Calabria A, Tiyaboonchai A, et al. AAV integration in human hepatocytes. Mol Ther. 2021;29(10):2898–2909. doi: 10.1016/j.ymthe.2021.08.031
   PubMed Web of Science ®Google Scholar
• Sabatino DE, Bushman FD, Chandler RJ, et al., American Society of Gene and Cell Therapy (ASGCT) Working Group on AAV Integration. Evaluating the state of the science for adeno-associated virus integration: an integrated perspective. Mol Ther. 2022 Aug 3;30(8):2646–2663. doi: 10.1016/j.ymthe.2022.06.004.
   PubMed Web of Science ®Google Scholar
• Thornburg CD, Simmons DH, von Drygalski A. Evaluating gene therapy as a potential paradigm shift in treating severe hemophilia. BioDrugs. Jul 20 2023;37(5):595–606. doi: 10.1007/s40259-023-00615-4
   PubMed Web of Science ®Google Scholar
• Noone D, Astermark J, O’Mahony B, et al. The journey of gene therapy in haemophilia – putting the patient at the centre of the hub and spoke model. J Haemophil Pract. 2023;9(1):156–166.
   Google Scholar
• Hemgenix® Prescribing Information. CSL Behring LLC. King Of Prussia, PA [ updated 2022 Nov; cited 2023 Oct 25]. Available from: https://labeling.cslbehring.com/PI/US/Hemgenix/EN/Hemgenix-Prescribing-Information.pdf
   Google Scholar